GlassScriptPhysician profile
Tonia D Bailey
NPI 1144671942
$1,095.30
in general payments reported to CMS, 2019-2025
21 companies · $958 in 2025
The $958 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $137 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $322.24 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $105.91 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $99.61 | 2025 | Mounjaro, Zepbound |
| Amgen INC. | $90.58 | 2025 | Krystexxa, Repatha, Evenity |
| Pfizer INC. | $70.47 | 2025 | |
| Astellas Pharma US INC | $46.38 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $37.10 | 2025 | Shingrix, Bexsero, Arexvy |
| Astrazeneca Pharmaceuticals LP | $35.97 | 2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $30.31 | 2025 | |
| Zimmer Biomet Holdings, INC. | $27.11 | 2025 | Persona |
| Eisai INC. | $26.79 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $26.08 | 2025 | Uptravi, Opsumit |
| Mayne Pharma Commercial LLC | $23.51 | 2025 | |
| Collegium Pharmaceutical, INC. | $23.46 | 2025 | Jornay Pm |
| Hologic Sales and Service, LLC | $23.27 | 2024 | Thinprep 2000 Processor, Aptima |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.85 | 2025 | Freestyle Libre 3 |
| Organon LLC | $19.92 | 2024 | |
| Dynavax Technologies Corporation | $18.70 | 2025 | Heplisav-B |
| Shield Therapeutics INC | $15.52 | 2025 | |
| Abbvie INC. | $14.82 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.70 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonia Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.